Biogenic Nanotherapeutics

The combination of incorrect and overly frequent application of antibiotics and insufficient hygiene measures in hospitals leads to a worldwide rise in the number of resistant germs for which ever less effective therapies exist. The scientists of the "Biogenic Nano-Therapeutics" group develop intelligent mechanisms of action and nano-systems that transport known antibiotics specifically to infected sites in the human body. In their work, they use modern biomimetic systems that utilise mechanisms found in nature or are derived from them. This allows for an effective control of pathogenic bacteria with minimal adverse effects.

Leader

Dr Gregor Fuhrmann

Nature shows us how information can be efficiently transported from A to B. We study these biological principles and want to derive novel therapeutic options from them.

GREGOR FUHRMANN

Gregor Fuhrmann majored in pharmacy in Berlin and graduated in 2008 with the final university examination ("Staatsexamen"). He received his doctoral degree in 2012 from the Eidgenössische Technische Hochschule (ETH) Zurich at the Drug Formulation and Delivery department under the direction of Prof Jean-Christophe Leroux. He received the ETH Medal for his doctoral thesis and the Rottendorf Europapreis award for excellent pharmaceutical research. He then worked as a postdoc at the Department of Materials and Department of Bioengineering at the Imperial College London in the group of Prof Molly M. Stevens (2013-2016).  He received both a Marie Curie Intra European Fellowship from the European Union and a postdoctoral scholarship from the German Academic Exchange Service (DAAD) for this.

At the end of 2015, he successfully applied for the "NanoMatFutur" talent-development programme of the German Federal Ministry for Education and Research and has been head of the "Biogenic Nano-Therapeutics" (BION) junior research group at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) since December 2016.

For his innovative work in the field of pharmaceutical technology, Gregor Fuhrmann received the technology prize of the Galenus Foundation in 2017 and in 2019 was awarded the “Horst-Böhme” Award for Young Investigators from the German Pharmaceutical Society (DPhG).

PrintSend per emailShare